Around 25,000 people annually worldwide are subject to the procedure of allogeneic hematopoietic stem cell transplantation (HSCT).
Each year around 25,000 people globally undergo an allogeneic hematopoietic stem cell transplantation (HSCT). With the number of transplantation procedures growing steadily, post-transplant care is becoming an essential part of work at transplant centres and general practitioners' offices. Advancements in technology and supportive therapies extend long-term survival of patients after hematopoietic stem cell transplantation which increases the risk of complications resulting from exposure before, during and after transplant procedures. The complications may lead to significant morbidity, deteriorated quality of life and late mortality in patients who have received hematopoietic stem cells. Statistical analyses have shown that the survival rate of post-HSCT patients is ca. 30% lower than expected, and that infections, organ failure and secondary cancers lead to mortality in this patient group [1, 2, 5, 21] .
TASKS OF OUTPATIENT TRANSPLANT CLINICS

Remission control
The key responsibility of an outpatient transplant clinic is controlling the remission of the primary condition. At the initial consultation, the clinic should estimate the individual risk of recurrence on the basis of the patient's response to prior treatment, assess the extent and severity of the minimal residual disease and identify the specific tumour markers (phenotypic, cytogenetic and molecular markers) which will be used in scheduled tests of bone marrow and peripheral blood [1] [2] [3] . Following an allogeneic hematopoietic stem cell transplantation, the patient becomes a chimera because he/she has genetically distinct cells from the donor in his/ her bone marrow and peripheral blood. The graft-versus-host disease (GvHD) [1] [2] [3] . A range of different cell populations in the blood and bone marrow may be used for chimerism testing. From the prognostic perspective, the most valuable counts are those performed on cell lines from which the cancerous cells originate. It is also highly beneficial to test chimerism in the T-lymphocyte subpopulation due to its role in the graft-versus-leukaemia/cancer (GvL) effect.
A chimerism test with the longest history is the blood type test which is conducted when the recipient and donor have different erythrocyte antigens. This test, however, does not yield a precise result due to peri-operative transfusions and a long lifespan of erythrocytes. When analysing chimerism in sex-mismatched donor/recipient pairs, a fluorescence in situ hybridization (FISH) method can be applied using sex chromosome-specific probes. In case of histoincompatibility between the donor and the recipient, a human leukocyte antigen (HLA) test can be performed. At present, the most commonly used chimerism tests include highly sensitive and informative molecular techniques such as the detection of donor-and recipient-specific microsatellite markers using the short tandem repeats-polymerase chain reaction (STR--PCR) method, and the real-time polymerase chain reaction (RT-PCR) method exploring the biallelic polymorphism found in the genome.
The most desirable outcome is a complete chimerism (CC) which is established when only the donor's characteristics and DNA are present in the sample (> 95%). This status is associated with a complete remission and a progression-free survival [3] . When both the donor's and the recipient's DNA is detected in the sample, a mixed chimerism is identified which can be stable or transient. A stable mixed chimerism (SMC) is recognised when the donor/recipient cell proportion remains steady long after HSCT and a transient mixed chimerism (TMC) is identified when the proportion of the donor's characteristics and DNA grows in subsequent tests (by 5%) until a CC is achieved. A SMC occurs at an early stage after a transplantation with a reduced-intensity conditioning (RIC) regimen. However, when a SMC persists for a longer period, it may indicate that an immunological tolerance was established between the donor and the recipient cells and is a sign of an increased risk of recurrence (due to a weaker GvL effect). In case of a mixed chimerism, it is recommended to test chimerism once a week or 2 weeks until day 100, and afterwards once a month up to 18 months until a complete chimerism is confirmed by two consecutive tests. When the percentage share of the recipient's DNA increases by 5% in consecutive tests, then a progressive mixed chimerism (PMC) is identified which may be regarded as evidence of recurrence at the molecular level, and indicates that immunomodulative treatment should be initiated (immunosuppressive treatment need to be discontinued and donor lymphocyte infusions should be considered).
Allo-HSCT are increasingly often performed on patients at a high risk of recurrence, therefore it has become very important in recent years to plan a post-transplant consolidation therapy to sustain the remission effect (e.g. by use of demethylating agents in myelodysplasia and tyrosine-kinase inhibitors in case of BCR/ABL rearrangements etc.) and to competently use donor lymphocyte infusions for treatment of the residual disease.
Preventing the graft-versus-host disease
The graft-versus-host disease is one of the most serious and This dose should be maintained until the dosage of calcineurin inhibitors is tapered. gens. Only at six months after the transplant, the thymus is ready to take responsibility for the regeneration process, bringing the T-lymphocyte count to normal levels and restoring their functions. Thanks to the rearrangement of genes encoding the T-cell receptor which takes place in the thymus, the virgin lymphocytes are capable of responding to a whole range of pathogens to which the host is exposed.
Assessment of immune reconstitution
Age is the key factor determining the role played by thymus 
Haemophilus influenzae B
• It is recommended to immunise the patient with 3 doses of conjugate vaccine at one-month intervals at 6 to 12 months after the transplantation.
Neisseria meningitidis
• Patients need to receive one dose of a conjugate vaccine at 6 to 12 months after the transplantation. A proposed vaccination plan is shown in Table 2 .
Patients after allogeneic hematopoietic stem cell transplantations experience pathological symptoms in all organs. These topics will be discussed in a separate paper.
